From Diabetes to Duchenne: EMA’s Defining 2025 Drug Calls

The European regulator’s anniversary year featured first-in-class therapies, rare-disease advances, safety warnings, and new rules reshaping how medicines reach patients. Medscape News Europe

Read the full article on medscape.com